objective To compare the cost-effectiveness of L-AmB with that of Sb V and AmB-D, for the treatment of mucocutaneous leishmaniasis in a hospital in north-east Brazil.
Introduction
As one of the six most clinically important infectious diseases, leishmaniasis is a global public health concern [1] . In 2010, WHO estimated 12 million people around the world to be infected with one of the different species of Leishmania, with 1-2 million incident infections each year [2, 3] .
Mucocutaneous leishmaniasis affects the skin and mucosae, occurs worldwide and affects individuals in 88 countries in Africa, Asia, Europe and the Americas. In humans, the lesions caused by the intense inflammatory process secondary to the presence of the parasite can lead to physical deformities resulting in psychological, social and economic impacts [4] .
Currently, in Brazil, the main options available for leishmaniasis drug therapy allow treatment in both outpatient and inpatient settings, depending on the clinical presentation, severity and comorbidities [5] . Despite increasing rates of resistance [2] , pentavalent antimony (Sb V ) remains the first-line therapy against most species of Leishmania because of its low cost and the relatively low incidence of adverse effects. Although rare, cardiotoxicity and sudden death can occur [6, 7] . Alternatively, amphotericin B (AmB) is another more potent, commercially available, leishmanicidal drug [8] . However, its conventional formulation is associated with a high rate of infusion-related adverse effects (such as fever and chills), electrolyte disturbances (hypokalemia and hypomagnesemia) and nephrotoxicity, which occurs in 30-80% of patients treated with AmB [9, 10] .
Lipid formulations of AmB have been successfully used in the treatment of leishmaniasis [2, 11, 12] . Liposomal amphotericin B (L-AmB), first introduced in 1996, is the more widely studied lipid formulation in clinical trials [23] . This formulation is significantly less nephrotoxic than amphotericin B deoxycholate (AmB-D) and offers a shorter duration of treatment than Sb V or AmB-D [13, 14] . L-AmB has been safely and effectively administered in very high doses for a few days or in a single day [15, 16] . The high cost of lipid formulations is the main barrier to their widespread use in the pharmacotherapy of leishmaniasis [17] .
Despite the reduction in the length of stay in hospital and frequency of adverse effects seen with L-AmB, the drug acquisition costs have influenced public policies in the drug therapy of leishmaniasis. Paradoxically, there is a scarcity of economic analyses that consider both measures of effectiveness and the total costs incurred during hospitalisation, treatment-related complications, adverse effects and other measures frequently used in the decision-making process [18] . This study compared the costeffectiveness of L-AmB with that of Sb V and AmB-D for the treatment of mucocutaneous leishmaniasis in patients of a hospital in north-east Brazil.
Methods

Design
An economic model was developed to evaluate the costeffectiveness of the three intravenous alternatives available in Brazil for the treatment of mucocutaneous leishmaniasis, from the perspectives of the hospital and public health manager.
Data source for economic model
We retrospectively evaluated the data of patients treated for mucocutaneous leishmaniasis between January 2006 and December 2012 at the University Hospital Professor Edgard Santos, a 333-bed facility in north-east Brazil. Leishmaniasis was treated in accordance with guidelines of the Brazilian Ministry of Health.
Eligible patients included those diagnosed with mucocutaneous leishmaniasis, treated with Sb V , AmB-D or LAmB, aged 18 or older. Patients' data were collected from the medical records for one year after the course of treatment. Patients with missing data were excluded.
Clinical information such as medical history, comorbidities, adverse events, complications and health outcomes was extracted. Data on medicine consumption, laboratory tests, image exams, appointments with specialists and other costs incurred during hospital stay were obtained from the computerised hospital management system.
Leishmaniasis treatment and reimbursement in the Brazilian healthcare system
In the Brazilian Unified Health System (SUS), payment for treatment is determined by an official prefixed index (SUS TABLE) [12] , for each disease according to the International Code of Diseases that resulted in the hospitalisation. The SUS TABLE also describes the amount to be paid for procedures and exams, for some specific diseases. In some cases, the reimbursement is replaced by the direct supply of medicines, such as for leishmaniasis, where the Sb V and L-AmB are purchased and provided by state and federal governments, respectively, while AmB-D is acquired directly by the hospital. Sb V is available for any patient with a confirmed or suspected diagnosis of leishmaniasis if drug therapy is indicated. Those individuals that fail treatment twice or have been intolerant to Sb V are treated with AmB-D, as this is not contraindicated. On the other hand, L-AmB is reserved exclusively for patients that meet criteria established by the national guideline, which restricts its use for older people, children <1-year-old, and patients presenting with treatment failure or are intolerant to both Sb V and AmB-D.
Economic model
A timeline analysis in a Markov model ( Figure 1 ) was built to evaluate the cost of the treatment and the costeffectiveness between L-AmB and the compared alternatives (Sb V and AmB-D). Transition states were defined according to the outcomes described in the Brazilian guideline, which states that a patient may complete the treatment with the first-line drug until cured or satisfactory clinical improvement is achieved, finish the treatment with clinical improvement but relapse within 12 months, require an early change in treatment due to therapeutic failure or adverse drug reactions, or die.
The analytical model was constituted by a decision tree followed by Markov cycles. A decision tree was used to describe the possible ways for each evaluated treatment. The time defined in this stage was based on the average time of a successful treatment with AmB-D, because the treatment with this option presents the longer duration among the three treatments in our comparison. This was an attempt to standardise the observation of the initial treatment.
A 30-day follow-up time is expected to be sufficient for evaluating the clinical response of mucocutaneous leishmaniasis patients. Therefore, according to the Brazilian guideline, there is a relapse when the clinical signs or lesions reappear, without the possibility of a reinfection, up to one year after finishing the treatment. In this model, the 30-day decision tree was extended with Markov cycles for 12 months (1 year). Markov cycles consisted of the following health states:
(i) success: signs and symptoms resolved without relapse until 12 months after; (ii) change of treatment due to (ii.1) failure-lack of clinical response or relapse within 12 months of finishing the treatment; or (ii.2) severe adverse events such as nephrotoxicity, hepatotoxicity, cardiotoxicity; (iii) death.
Data analyses were performed using STATA version 14.0 (StataCorp LLC, TX, USA), and economic modelling was performed using TreeAge Pro 2011 (TreeAge Software Inc., MA, USA).
Some assumptions were made for the model based on the national guidelines and the data observed within the historical cohort. 1 Patients who needed to be newly treated within 12 months of finishing, the previous one were considered to have a therapeutic failure; 2 Patients requiring readmission after 12 months of successful treatment were considered to have reinfections; 3 For relapsed patients treated for leishmaniasis prior to inclusion in our cohort, data from the previous treatment were not considered; 4 Treatment switches secondary to treatment failure or adverse drug reactions were analysed for a single temporal line in the model; 5 In the transition states due to therapeutic failure or adverse drug effects, the two other options of treatment, and their respective probabilities of use, were included in the model.
Input parameters
For each treatment arm, the parameters inputted into the analytic model, such as rates of success, deaths, switches due to treatment failure or adverse drug effects, and the time needed for transition, were based on the retrospective data from our cohort study. Figure 1 presents the transition probabilities between the health states and other variables used in the model.
The costs per unit of health resource consumed are presented from the hospital and health system perspective in Table 1 . Aiming to unify the costs over time, current values (2016) were used in the analysis. Unitary values relating to hospital stay, procedures and supporting diagnosis were extracted from SUS TABLE, while those pertaining to drugs, professionals and hospital supplies consumed were extracted from the hospital management system, except for Sb V and L-AmB as previously explained. Their values were obtained from the Drug Market Regulation Chamber. All monetary values were converted from Brazilian Real to US dollar using the average exchange rate for the year 2016 (R$ 3.501 = US$ 1.00).
Costs in the decision tree were calculated by summing (i) the cost of an entire treatment with each drug used for leishmaniasis therapy (without switch); (ii) costs of hospital expenses (diagnosis and monitoring exams, drugs to treat comorbidities or adverse drug events) and hospital care (including stay and professional fees).
From this sum, the 'average daily cost of hospitalisation in a successful treatment' was obtained. Similarly, the 'average daily cost of hospitalisation when a switch was needed' was calculated. All the costs used in the model are detailed in Table 2 .
Sensitivity analysis
First, a sensitivity analysis was performed to identify the variables with a higher impact on the results, followed later by a probabilistic sensitivity analysis to assess a confidence interval for the cost-effectiveness ratio estimated. Finally, faced with the uncertainty relating to some parameters, a one-way sensitivity analysis was performed on the results of the model.
Health economic evaluation
The basic outcomes were the total costs (including those incurred during the diagnosis, treatment and monitoring), cure rate, incidence of adverse drug effects, rate of changes in therapy due to treatment failure or adverse effects, and length of hospital stay. Next, the net values and cost-effectiveness ratio were calculated for each treatment option used and used for comparison via the incremental cost-effectiveness incremental ratio (ICER) and the net monetary benefit (NMB).
Results
In the seven-year period during which this study was conducted, 74 patients met the criteria for inclusion in the historical cohort. One patient was excluded because only data of the first day of treatment were available in medical record. No data about follow-up or outcome was found. Table 2 shows general information about 73 hospitalised patients for the treatment of mucocutaneous leishmaniasis from 2006 to 2012.
The highest rate of success was observed in patients who entered into the cohort through the L-AmB arm, in comparison with the Sb V and AmB-D arms. Table 3 shows the main outcomes assessed in the three treatment groups and the effectiveness measures used in the economic model.
As shown in Figure 2 , the follow-up analysis in the Markov model showed that after 2 months of initiating treatment, 82.6% (95% confidence interval [ , that is the current WTP within the study locality.
Cost-effectiveness
The one-way sensitivity analysis ( Figure 7 ) demonstrated that with a WTP of US$ 6855.18, the probability of L-AmB being more cost-effective than the other two treatments was 40% and should reach 90% for a WTP of US$ 11 996.57 if the current cost of a vial of L-AmB is maintained.
Discussion
In this study, L-AmB was cost-effective when used as the first-line therapy in hospitalised patients with mucocutaneous leishmaniasis from both the perspective of the health system and the hospital. This result encourages the negotiation of the acquisition costs of L-AmB and the mean price, which the health system will be willing to pay for each patient treated. L-AmB was the most effective and safe treatment, reaching cure rates four times higher than Sb V and about 1.5 times higher than AmB-D. Furthermore, treatment with L-AmB was associated with lower rates of serious adverse effects and necessity for shifting treatment due to adverse events, as shown in previous studies. Therefore, these advantages justify the use of L-AmB as a first-line therapy in countries with a low incidence of leishmaniasis, with fewer budget restrictions, or in health services with private financing [19] . Although there is a lack of evidence to definitively prove the superiority of using L-AmB to treat leishmaniasis, especially in the mucocutaneous form, some studies with small sample sizes have supported the decision-making process due to the scarcity of other well-designed studies and the lack of therapeutic alternatives [6, 7, 10, 13, 14] . That decision is reinforced by larger studies that demonstrate the safety of L-AmB compared to AmB-D in the treatment of fungal infections [10, [20] [21] [22] .
The high cost of L-AmB is a relevant barrier to its use for the treatment of leishmaniasis in developing countries, which are more affected by the disease [18] . This access is also hampered by the absence of quality economic analyses, specially tailored to the local setting, which would support the decision-making in the opposite direction. However, this gap induces health systems to define the first-line therapy only based on direct drug acquisition costs [5, 7] . In the light of this gap, we built an economic model that demonstrated that the total cost of treating a hospitalised patient with leishmaniasis, even when started with current cheaper first-line options, is high for the health system. This total cost is mainly related to the frequent need of drug replacement due to the adverse effects or treatment failure observed with Sb V and AmB-D. Thus, our data provide information to the local health system to review its policy for the treatment of leishmaniasis, notably to patients that need hospitalisation.
By changing the cost of a vial of L-AmB in the Monte Carlo simulation, the model showed that the differences between the cost-effectiveness ratios of compared alternatives could be reduced through a price negotiation for LAmB and by reviewing the WTP for leishmaniasis in the health system. Deals have been made with the manufacturer (GILEAD) for a reduction in the price of L-AmB in several countries, including Brazil. However, in our country, this subsidisation is restricted for the treatment of special cases according to the national guideline, while the vast majority of patients begin treatment with a less effective and more toxic drug, which, results in a longer course of treatment. Therefore, our results should be used by decision-makers to define an economically viable WTP for the health system that takes into consideration the substantial reduction in the time needed to complete treatment and the risk of serious adverse effects, which are both provided by L-AmB and not by current first-line drugs.
The Markov modelling based on a retrospective study we have conducted allowed a better approximation of the observed costs to real figures as it incorporated the possible transition states among the treatment options to the definition of total costs. Interestingly, our model demonstrated that a reduction in the cost of L-AmB likewise significantly decreases the total cost of the other two therapies combined leading to an increase in their effectiveness, as a significant number of patients were intolerant or experienced treatment failure on Sb V and AmB-D, necessitating their switch to L-AmB. During the sensitivity analysis, the interrelationship among the treatment arms, due to the high rates of adverse effects of Sb V and AmB-D, resulted in significant changes in the NMB after a reduction in the cost of a vial of L-AmB.
Although miltefosine is not available for the treatment of human tegumentary leishmaniasis in Brazil, in 2016, the National Committee for Technology Incorporation recommended its inclusion, based on clinical trials where miltefosine cure rates were similar to Sb V with less adverse effects [23, 24] . However, the use of miltefosine as first-line therapy has faced difficulties in developing countries due to problems with adherence in real conditions of use. Thus, supposing its inclusion in Brazilian guidelines, this change in the scenario could affect our conclusions for the future. However, we do not believe this effect to becomes significant since current evidence applies to combination therapy including miltefosine for resistant infection rather than miltefosine monotherapy, a situation not common in Brazil.
Using an economic model based on retrospective data for decision analysis in health care is a limitation of this study. However, this type of data was easy to use in the economic analyses, especially sensitivity analysis, which was central to our model, as it favoured a large amplitude of NMB with variations in the main predictor variable (cost of a vial of L-AmB) and WTP for the health system. There was no significant waste caused by loss of data within the medical records, which increases the reliability of our results.
The differences observed between treatment groups with the number of patients or comorbidities, as seen in Table 2 , could be a possible source of bias in our model. But changing these and other parameters in the sensitivity analysis did not significantly impact the final effectiveness measures, which can be justified by the expected effect in both the comparisons of effectiveness between L-AmB vs. Sb V and the safety of L-AmB vs. AmB-D, as described in previous studies [5] .
Conclusion
L-AmB is a cost-effective alternative in comparison with Sb V or AmB-D owing to its higher effectiveness, safety and shorter length of treatment for inpatients with mucocutaneous leishmaniasis. The degree of the net benefit is related to the extent of reduction in the drug acquisition costs and the review of the WTP by the management of the health system.
